The rise of next generation sequencing (NGS) has opened up new opportunities for translating high-throughput functional genomics into clinical practice. NCT MASTER provides the complete workflow for high-throughput diagnostics and comprises all steps from bedside to bench and back, including quality-assured sample acquisition by surgery or biopsy; histopathological evaluation; quality-managed analyte extraction in a central Sample Processing Laboratory; NGS and other “omics” technologies; bioinformatic processing according to standardized pipelines; GLP-certified validation of variants and clinical evaluation by a molecular tumor board of translational oncologists, bioinformaticians, molecular biologists, and pathologists.
NCT MASTER Workflow
NCT MASTER enables clinical investigators to rapidly implement novel molecular analyses in the patient context.
By combining forces between genomics, systems biology and translation, the Heidelberg Center for Personalized Oncology (DKFZ-HIPO) and NCT POP integrate the best research groups in functional genomics, systems biology and translational oncology under a unified organizational structure. The center consists of three programs: Genome Analysis (HIPOgen, head: Peter Lichter), Systems Biology (HIPOsys, head: Roland Eils) and NCT Precision Oncology Program (HIPOmed, head: Christof von Kalle).
The technology platform for high-throughput sequencing, data analysis and imaging features all required technology for pursuing the center’s ambitious goals. In particular, it integrates the next generation sequencing platform for the analysis of whole genomes, methylomes and transcriptomes with a bioinformatics platform that hosts Germany’s largest data facility in the life sciences together with a very strong genome data analysis group that oversees the entire data analysis in all three German ICGC projects.
Within HIPOmed NCT POP directly links the activities within HIPO to clinical programs and allows the rapid transfer of scientific knowledge into clinical applications working on molecular target identification and drug screening in primary cancer tissues to discover predictive and prognostic markers and clinically develop new cancer targets.